Safety of continuous use of Apixaban, Rivaroxaban and Dabigatran in patients undergoing cardiac implantable electronic device implantation in a real-world cohort
Overall and cardiovascular-related mortality after complications of cardiac implantable electronic devices: preliminary results from the IMPACT registry
Speaker:
Associate Professor F. Guerra (Ancona, IT)